News and Insights

Strategic Planning and New Business Models

Is Medicare Price Negotiation the Solution We Need?

Numerof Brief

On August 29th, the Biden Administration named the 10 drugs that will be subject to price negotiation with Medicare in the initial implementation of the Inflation Reduction Act (IRA) of 2022. Release of the list marked a milestone in a decades-long effort by Democrats to use the purchasing power of…

Competitive Strategy for Mid-Sized Payers: Creative Collaborations are Key

Chief Healthcare Executive

Long-term success in any industry requires ongoing investment to progress customer-facing capabilities and internal operations. Health insurance is no exception and – one could argue – due to often thin differences among competitors, is a side of the health care ecosystem where smart reinvestment can create the margin to win…

Numerof State of Population Health Survey

Population health management has been a national topic of conversation, but to date little effort has been devoted to tracking the actual progress that’s been made toward this new model of care. Now in its seventh year, Numerof’s State of Population Health survey provides an in-depth, national look at the pace…

The Numerof 2023 Global Pharma Outlook


As our Numerof 2023 Global Pharma Outlook infographic illustrates, this year’s story for pharmaceutical manufacturers will be about continuing to adapt to pressures on price, especially mandated government negotiation, and demands for value while dealing with the long-term effects of the pandemic.